Company intelligence / Profile preview

Gynica

Jerusalem, Jerusalem District, Israelgynica.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Gynica has launched a first-in-human Phase 1 clinical trial of its proprietary intravaginal cannabinoid-based formulations for endometriosis. The study evaluates safety, tolerability, and pharmacokinetics of their IntraVag platform and two drug candidates. Pending positive results, they plan to advance rapidly into Phase 2 efficacy trials. Preclinical research suggests potential benefits in alleviating endometriosis-associated pain by targeting the endocannabinoid system locally with minimal systemic side effects.

Therapeutic areas: Women's Health
Modalities: Small moleculeCannabinoid-based therapyDevice
Industry: Biotech

Drug pipeline

1 asset

IntraVagS301

Unknown

Partnerships

Careggi University Hospital, Florence, Italy – site for first-in-human clinical trial led by Prof. Felice Petraglia

Beyond the preview

Go deeper on Gynica.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Gynica.

Explore the full profile